ES2044829T3 - Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos. - Google Patents

Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.

Info

Publication number
ES2044829T3
ES2044829T3 ES90915877T ES90915877T ES2044829T3 ES 2044829 T3 ES2044829 T3 ES 2044829T3 ES 90915877 T ES90915877 T ES 90915877T ES 90915877 T ES90915877 T ES 90915877T ES 2044829 T3 ES2044829 T3 ES 2044829T3
Authority
ES
Spain
Prior art keywords
spin
trapping
administration
compositions
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90915877T
Other languages
English (en)
Other versions
ES2044829T1 (es
Inventor
John M Carney
Robert A Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/422,651 external-priority patent/US5025032A/en
Application filed by Oklahoma Medical Research Foundation, University of Kentucky Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of ES2044829T1 publication Critical patent/ES2044829T1/es
Application granted granted Critical
Publication of ES2044829T3 publication Critical patent/ES2044829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES CONTENIENDO COMO INGREDIENTE ACTIVO UN REACTIVO QUE ES ATRAPADO EN EL CENTRIFUGADO, PREFERENTEMENTE (ALFA)-FENIL BUTIL NITRONA (PNB), O SUS DERIVADOS QUE SON ATRAPADOS EN EL CENTRIFUGADO, EN UN PORTADOR FARMACEUTICO APROPIADO PARA LA ADMINISTRACION A UN PACIENTE, PARA EL TRATAMIENTO O PREVENCION DE SINTOMAS ASOCIADOS CON ATAQUES U OTROS DAÑOS ISQUEMICOS, ENVEJECIMIENTO U OTRAS CONDICIONES ASOCIADAS CON EL DAÑO OXIDATIVO A LOS TEJIDOS. PARA LA PREVENCION O TRATAMIENTO DEL DAÑO COMO RESULTADO DE LA ISQUEMIA, LAS COMPOSICIONES SE ADMINISTRAN ANTES O DURANTE LA ISQUEMIA EN UNA DOSIS EFICAZ, PARA PREVENIR O INVERTIR LA PREDISPOSICION DE LAS CELULAS AL DAÑO RESULTANTE DEL EMPOBRECIMIENTO DE ATP Y EL DAÑO DE LA GENERACION DE RADICAL LIBRE QUE SIGUE A LA REPERCUSION. EJEMPLOS DE ENFERMEDADES QUE PUEDEN SER TRATADAS INCLUYEN; ATAQUES, MENINGITIS, PERDIDA NEURONAL PROGRESIVA DEBIDO A LA ENFERMEDAD DE PARKINSON, DEMENCIA SENIL, DROGADICCION, ENFERMEDADES QUE APARECEN POR LAEXPOSICION A OXIGENO A GRAN PRESION O ENTORNOS CON OXIGENO ENRIQUECIDO, Y UNA HEMORRAGIA DEL TEJIDO NERVIOSO COMO RESULTADO DE UN TRAUMATISMO. PARA EL TRATAMIENTO DEL ENVEJECIMIENTO, LAS COMPOSICIONES SE ADMINISTRAN PREFERENTEMENTE UNA O DOS VECES AL DIA MEDIANTE ADMINISTRACION ORAL DURANTE UN PERIODO DE DOS SEMANAS. SE OBSERVA UNA SIGNIFICANTE REDUCCION DE PROTEINAS OXIDADAS Y RECUPERACION DE MEMORIA AL CABO DE SIETE DIAS DESPUES DEL COMIENZO DEL TRATAMIENTO.
ES90915877T 1989-10-17 1990-10-17 Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos. Expired - Lifetime ES2044829T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/422,651 US5025032A (en) 1989-10-17 1989-10-17 Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US58917790A 1990-09-27 1990-09-27

Publications (2)

Publication Number Publication Date
ES2044829T1 ES2044829T1 (es) 1994-01-16
ES2044829T3 true ES2044829T3 (es) 1995-01-16

Family

ID=27025701

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90915877T Expired - Lifetime ES2044829T3 (es) 1989-10-17 1990-10-17 Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.

Country Status (11)

Country Link
US (4) US5405874A (es)
EP (1) EP0496796B1 (es)
JP (5) JP2620413B2 (es)
KR (1) KR960008230B1 (es)
AT (1) ATE110565T1 (es)
AU (4) AU653921B2 (es)
CA (1) CA2069961C (es)
DE (1) DE69012138T2 (es)
DK (1) DK0496796T3 (es)
ES (1) ES2044829T3 (es)
WO (1) WO1991005552A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013017715A3 (es) * 2011-08-01 2013-06-13 Consejo Superior De Investigaciones Científicas (Csic) Quinolilnitronas

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2044829T3 (es) * 1989-10-17 1995-01-16 Oklahoma Med Res Found Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
DE69232263T2 (de) * 1991-06-18 2003-06-18 Oklahoma Medical Research Foundation, Oklahoma Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
US5292746A (en) * 1991-09-12 1994-03-08 Merrell Dow Pharmaceuticals Inc. Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
NZ244268A (en) * 1991-09-12 1994-09-27 Merrell Pharma Inc N-oxide quinoline derivatives and pharmaceutical compositions
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
WO1995011908A1 (en) * 1993-10-25 1995-05-04 Oklahoma Medical Research Foundation Novel phosphorus-containing spin-trap compositions
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
FR2731428B1 (fr) * 1995-03-06 1997-06-06 Centre Nat Rech Scient Derives phosphoryles de nitrones, leur procede de preparation et compositions les contenant
EP0863878B1 (en) * 1995-09-11 2003-01-08 Aventis Pharmaceuticals Inc. Cyclic nitrones and pharmaceutical compositions containing them
WO1997019054A1 (en) * 1995-11-17 1997-05-29 Florida International University Azulenyl nitrone spin trapping agents, methods of making and using same
AU725432B2 (en) * 1996-04-17 2000-10-12 Centaur Pharmaceuticals, Inc. Nitrone free radical trap treatment of dementia associated with AIDS virus (HIV-1) infection
TW450952B (en) * 1996-04-23 2001-08-21 Centaur Pharmaceuticals Inc Ophthalmic pharmaceutical compositions comprising a nitrone compound
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
EP1021430A1 (en) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) * 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
AU742768B2 (en) * 1998-01-16 2002-01-10 Renovis, Inc. Thioether furan nitrone compounds
CA2318555A1 (en) * 1998-01-16 1999-07-22 Yong-Kang Zhang Thiophene nitrone compounds
RU2225392C2 (ru) * 1998-06-24 2004-03-10 Реновис, Инк. Альфа-арил-N-алкилнитроны, фармацевтические композиции (варианты), способ ингибирования нейродегенеративных заболеваний, способ лечения и способы профилактики (варианты)
AU750599B2 (en) 1998-07-17 2002-07-25 Renovis, Inc. Alpha-(2-hydroxyphenyl) nitrone compounds, pharmaceutical compositions containing the same and their use for treating inflammation
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6339102B1 (en) * 1999-06-09 2002-01-15 The United States Of America As Represented By The Secretary Of The Army Method and composition for treating and preventing retinal damage
EP1267860A1 (en) * 2000-03-30 2003-01-02 Oklahoma Medical Research Foundation Butylnitrone containing compositions for inhibition of cancer development
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US6762322B1 (en) * 2002-12-20 2004-07-13 Goodyear Tire & Rubber Company Preparation of nitrone derivatives
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
US7125934B1 (en) 2005-06-28 2006-10-24 The Goodyear Tire & Rubber Company Functionalization of living rubbery polymers with nitrones
JP5236641B2 (ja) * 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
AU2009214727B2 (en) 2008-02-12 2014-12-11 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
WO2009110585A1 (ja) * 2008-03-07 2009-09-11 国立大学法人熊本大学 電子スピン共鳴測定用試料溶液及びその乾固物，並びにそれらを用いた測定方法
BRPI1013739A2 (pt) * 2009-04-20 2016-04-05 Volvo Constr Equip Ab sistema e método de pavimentação integrados.
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
DE102011088787A1 (de) 2011-12-16 2013-06-20 Evonik Industries Ag Siloxannitrone und deren Anwendung
WO2022169642A1 (en) * 2021-02-08 2022-08-11 Oklahoma Medical Research Foundation Okn-007 as a therapeutic agent for neurodegenerative diseases
DE102023124443A1 (de) * 2023-09-11 2025-03-27 Albert-Ludwigs-Universität Freiburg, Körperschaft des öffentlichen Rechts Vorrichtung zur Modifikation von Blut

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273702C (es) *
US35213A (en) * 1862-05-13 Improved hydrant
US35112A (en) * 1862-04-29 Improvement in head-rests for car-seats
US3396027A (en) * 1964-05-13 1968-08-06 Eastman Kodak Co Method of noodling gelatin dispersions
NL131665C (es) 1964-05-18
US3296145A (en) * 1965-10-21 1967-01-03 Millmaster Onyx Corp Quaternary ammonium-tertiary amine oxide compositions
US3775122A (en) 1967-07-28 1973-11-27 American Can Co Image production using photosensitive compositions of nitrone which is heat developed
US3849934A (en) * 1971-05-03 1974-11-26 Scm Corp Alpha-aryl-n-lower alkyl nitrone-containing compositions useful as anti-fungal agents
US3767818A (en) 1971-05-03 1973-10-23 Scm Corp Phenyl nitrone containing compositions useful as anti microbial agents
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
GB1588417A (en) * 1977-03-15 1981-04-23 Agfa Gevaert Photoresist materials
US4214003A (en) * 1977-10-06 1980-07-22 William H. Rorer, Inc. Method of treatment
US4197314A (en) * 1977-10-06 1980-04-08 William H. Rorer, Inc. Method of treating inflammation
US4224340A (en) * 1977-10-06 1980-09-23 William H. Rorer, Inc. Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
US4870002A (en) * 1981-04-07 1989-09-26 The United States Of America As Represented By The Secretary Of The Air Force Method of prevention of oxidative injury to cells
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals
USRE35213E (en) 1989-10-17 1996-04-16 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
ES2044829T3 (es) * 1989-10-17 1995-01-16 Oklahoma Med Res Found Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013017715A3 (es) * 2011-08-01 2013-06-13 Consejo Superior De Investigaciones Científicas (Csic) Quinolilnitronas

Also Published As

Publication number Publication date
JP2975587B2 (ja) 1999-11-10
US6107315A (en) 2000-08-22
EP0496796B1 (en) 1994-08-31
AU8310198A (en) 1998-12-24
ATE110565T1 (de) 1994-09-15
AU1131595A (en) 1995-03-23
AU710341B2 (en) 1999-09-16
ES2044829T1 (es) 1994-01-16
EP0496796A1 (en) 1992-08-05
AU6613390A (en) 1991-05-16
CA2069961A1 (en) 1991-04-18
AU692197B2 (en) 1998-06-04
DE69012138T2 (de) 1995-04-06
DK0496796T3 (da) 1994-10-03
KR960008230B1 (ko) 1996-06-21
WO1991005552A1 (en) 1991-05-02
AU653921B2 (en) 1994-10-20
KR920702220A (ko) 1992-09-03
US5578617A (en) 1996-11-26
AU8310298A (en) 1998-10-22
JP2620413B2 (ja) 1997-06-11
JPH10259128A (ja) 1998-09-29
US5405874A (en) 1995-04-11
AU710342B2 (en) 1999-09-16
JPH05505792A (ja) 1993-08-26
JP2002179563A (ja) 2002-06-26
JPH0925263A (ja) 1997-01-28
HK1007281A1 (en) 1999-04-09
JPH10259178A (ja) 1998-09-29
CA2069961C (en) 2000-05-02
US5681965A (en) 1997-10-28
DE69012138D1 (de) 1994-10-06
JP2816326B2 (ja) 1998-10-27

Similar Documents

Publication Publication Date Title
DK0496796T3 (da) Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse
AR240250A1 (es) Procedimiento para la preparacion de una nueva formualcion farmaceutica oral que contiene omeprazol como ingrediente activo.
SE8403487L (sv) Farmaceutisk komposition
NO884625D0 (no) N-substituerte derivater av 1-desoksynojirimycin og 1-desoksymannojirimycin, fremgangsmaate for deres fremstilling og deres anvendelse i legemiddel.
NO882732D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
ATA95989A (de) Pyridoncarbonsäurederivate und salze hievon, verfahren zur herstellung derselben und antibakterielle mittel, welche diese enthalten
IL85228A (en) 1-(4-hydroxy-3,5-di-tert.- butylbenzoyl) homopiperazine, various derivatives thereof, processes for the preparation of these and pharmaceutical compositions containing them
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
DE68923151D1 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DK393188A (da) Farmaceutisk praeparat til intranasal administrering
NO912414D0 (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
EE04551B1 (et) Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
EE04058B1 (et) Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DK0486586T3 (da) Kynurensyrederivater, fremstilling deraf og farmaceutiske præparater, der indeholder dem
BR9912423A (pt) Compostos e/ou derivados farmaceuticamente aceitáveis, composições farmacêuticas, métodos de tratamento das disordens neurológicas em pacientes e processos de preparação dos compostos ou derivados farmaceuticamente aceitáveis
ES2058316T3 (es) Procedimiento para la obtencion de un medicamento antitusigeno.
NO891678D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 496796

Country of ref document: ES